Overview

Pharmacokinetics and Pharmacodynamics Study of Saxagliptin in Healthy Subjects

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
To characterize the steady-state pharmacokinetics (PK) of 2.5 mg saxagliptin administered twice daily with meals to healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Treatments:
Saxagliptin